Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its position in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 3.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 368,455 shares of the biopharmaceutical company’s stock after purchasing an additional 13,941 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.75% of Puma Biotechnology worth $940,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of PBYI. SG Americas Securities LLC acquired a new position in shares of Puma Biotechnology in the third quarter valued at about $34,000. Patriot Financial Group Insurance Agency LLC grew its holdings in Puma Biotechnology by 72.7% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 8,000 shares during the period. Royce & Associates LP grew its holdings in Puma Biotechnology by 71.8% during the third quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 8,427 shares during the period. Victory Capital Management Inc. acquired a new stake in Puma Biotechnology during the second quarter worth about $54,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Puma Biotechnology during the second quarter worth about $58,000. 61.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PBYI has been the topic of several analyst reports. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a report on Wednesday, November 20th.

Puma Biotechnology Stock Performance

Shares of PBYI stock opened at $3.23 on Thursday. The company has a market capitalization of $158.56 million, a P/E ratio of 6.54 and a beta of 1.09. The business’s 50 day moving average is $2.79 and its two-hundred day moving average is $3.14. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a 12-month low of $2.22 and a 12-month high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter in the prior year, the business posted $0.12 earnings per share. Analysts expect that Puma Biotechnology, Inc. will post 0.29 EPS for the current fiscal year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.